Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

13 September 2026 · By · Wire by Fusion42

Published

13 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at marketbeat.com →

◆ Verified

Fusion42 · 13 September 2026 · Fusion42 review

Three small-cap biotech companies—Kodiak Sciences, Capricor Therapeutics, and Invivyd—have upcoming binary clinical trial results or FDA decisions in 2026 that could significantly impact their financial health and future prospects.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face looming decision points that will redefine market access and funding. Now is the time to map partnerships and capital readiness before these binary outcomes.

◆ Coverage

1 source · 13 Sep 2026

◆ Related on Wire

◆ Topics

BiotechbiotechFDA-decisionsclinical-trialssmall-cap2026-catalysts